The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...
Drs. Jessa Miller and Amrita Ray discuss the paradox of increasing incidence and decreasing mortality in AIFRS.
Treatment with dupilumab led to significant reductions in sinus opacification, nasal congestion and nasal polyps in patients with allergic fungal rhinosinusitis. Dupilumab, an interleukin-4 receptor ...
Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...
The FDA has approved dupilumab (Dupixent) to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older with a history of sinonasal surgery. The approval makes the drug the ...
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a ...
What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...
Patients receiving dupilumab showed clinical improvement in nasal congestion and smell, and were less likely to require systemic corticosteroids or additional sino-nasal surgery. The Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . The FDA based dupilumab’s approval on results from the LIBERTY-AFRS-AIMS trial. This marks the first treatment ...
Approval covers adults and children ≥6 years with prior sinonasal surgery, representing the first FDA-cleared pharmacologic option specifically for AFRS and dupilumab’s ninth U.S. indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results